• AWMSG advises the Welsh Government on the introduction of new medicines into Wales. Its health technology appraisal programme provides recommendations based primarily on clinical and cost-effectiveness.
• AWMSG adopts NICE guidance where available and appraises the remaining new medicines not on the NICE work programme. Should NICE issue guidance subsequently, however, its advice supersedes AWMSG recommendations.
• £800 million was spent in Wales on NHS medicines in [2015] [2016] (approx. 13% of health budget). Approximately 67% was spent in primary care and 33% in secondary care. The mean annual cost of AWMSG and NICE approved medicines in the period 2013-2016 was £144 million.
• Estimated medicine costs were obtained from company submissions to AWMSG.
• Observed medicine costs were obtained from primary and secondary care dispensing databases used in Wales.
• Databases do not show indications for which medicines were used, therefore medicines already in use for other indications were excluded.
• Estimated and observed costs were compared using Spearman correlation analysis.
• Mean expected and observed costs were compared using Wilcoxon Matched-pairs signed rank.
Introduction
• Analysis of the observed and company estimated costs of 49 medicines, appraised by AMWSG showed companies tended to overestimate the budget impact. Total costs for the batch of medicines analysed were overestimated by more than 40% in the first year of uptake rising to greater than 60% in the third year.
• Tendency to overestimate may be due to a more gradual uptake of the medicine following recommendation.
• Companies may wish to present an optimistic prediction of usage.
• An understanding of the validity of historical predictions may help to better inform future estimates of budget impact.
• To compare the estimated budget impact of medicines appraised by AWMSG with the observed expenditure in each of the first three years following positive recommendation. • The sum of the observed costs for the 49 medicines was compared to the sum of the estimated costs; total costs were overestimated by 41% (Year 1), 53% (Year 2) and 64% (Year 3).
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